1. Stone JH, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012;64:3061-3067.
[CROSSREF] [PUBMED] [PMC]
2. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-738.
[CROSSREF] [PUBMED]
3. Dahlgren M, Khosroshahi A, Nielsen GP, Deshpande V, Stone JH. Riedel’s thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 2010;62:1312-1318.
[CROSSREF] [PUBMED]
4. Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K, et al. Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med 2011;50:69-75.
[CROSSREF] [PUBMED]
5. Kawa S, Ota M, Yoshizawa K, Horiuchi A, Hamano H, Ochi Y, et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002;122:1264-1269.
[CROSSREF] [PUBMED]
6. Mahajan VS, Mattoo H, Deshpande V, Pillai SS, Stone JH. IgG4-related disease. Annu Rev Pathol 2014;9:315-347.
[CROSSREF] [PUBMED]
7. Komatsu K, Hamano H, Ochi Y, Takayama M, Muraki T, Yoshizawa K, et al. High prevalence of hypothyroidism in patients with autoimmune pancreatitis. Dig Dis Sci 2005;50:1052-1057.
[CROSSREF] [PUBMED] [PDF]
8. Kottahachchi D, Topliss DJ. IgG4-related thyroid diseases. Eur Thyroid J Forthcoming 2016.
9. Li Y, Nishihara E, Hirokawa M, Taniguchi E, Miyauchi A, Kakudo K. Distinct clinical, serological, and sonographic characteristics of Hashimoto's thyroiditis based with and without IgG4-positive plasma cells. J Clin Endocrinol Metab 2010;95:1309-1317.
[CROSSREF] [PUBMED] [PDF]
10. Graham A, Gilliland IC. Riedel's thyroiditis. Br Med J 1959;2:225-226.
[CROSSREF]
11. Fatourechi MM, Hay ID, McIver B, Sebo TJ, Fatourechi V. Invasive fibrous thyroiditis (Riedel thyroiditis): the Mayo Clinic experience, 1976-2008. Thyroid 2011;21:765-772.
[CROSSREF] [PUBMED]
12. Comings DE, Skubi KB, Van Eyes J, Motulsky AG. Familial multifocal fibrosclerosis. Findings suggesting that retroperitoneal fibrosis, mediastinal fibrosis, sclerosing cholangitis, Riedel's thyroiditis, and pseudotumor of the orbit may be different manifestations of a single disease. Ann Intern Med 1967;66:884-892.
[CROSSREF] [PUBMED]
13. Katz SM, Vickery AL Jr. The fibrous variant of Hashimoto's thyroiditis. Hum Pathol 1974;5:161-170.
[CROSSREF] [PUBMED]
14. Deshpande V, Huck A, Ooi E, Stone JH, Faquin WC, Nielsen GP. Fibrosing variant of Hashimoto thyroiditis is an IgG4 related disease. J Clin Pathol 2012;65:725-728.
[CROSSREF] [PUBMED]
15. Li Y, Bai Y, Liu Z, Ozaki T, Taniguchi E, Mori I, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto's autoimmune thyroiditis. Pathol Int 2009;59:636-641.
[CROSSREF] [PUBMED]
16. Takeshima K, Inaba H, Furukawa Y, Nishi M, Yamaoka H, Miyamoto W, et al. Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications. Thyroid 2014;24:736-743.
[CROSSREF] [PUBMED]
17. Takeshima K, Inaba H, Furukawa Y, Nishi M, Yamaoka H, Miyamoto W, et al. Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications. Thyroid 2014;24:736-743.
[CROSSREF] [PUBMED]
18. Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med 2006;354:2783-2793.
[CROSSREF] [PUBMED]
19. Bjergved L, Jorgensen T, Perrild H, Carle A, Cerqueira C, Krejbjerg A, et al. Predictors of change in serum TSH after iodine fortification: an 11-year follow-up to the DanThyr study. J Clin Endocrinol Metab 2012;97:4022-4029.
[CROSSREF] [PUBMED]
20. Rose NR, Rasooly L, Saboori AM, Burek CL. Linking iodine with autoimmune thyroiditis. Environ Health Perspect 1999;107(Suppl 5):749-752.
[CROSSREF] [PUBMED] [PMC]
21. Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG. Iodine-Induced hypothyroidism. Thyroid 2001;11:501-510.
[CROSSREF] [PUBMED]
22. Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009;23:703-712.
[CROSSREF] [PUBMED] [PMC]
23. Rapoport B, McLachlan SM. Graves' hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab 2014;99:4060-4061.
[CROSSREF] [PUBMED] [PMC]
24. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-2519.
[CROSSREF] [PUBMED]
25. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371-381.
[CROSSREF] [PUBMED] [PMC]
26. Minagar A, Alexander JS, Sahraian MA, Zivadinov R. Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opin Biol Ther 2010;10:421-429.
[CROSSREF] [PUBMED]
27. Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80-89.
[CROSSREF] [PUBMED]
28. Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 2015;21:22-34.
[CROSSREF] [PUBMED] [PMC]
29. Lee JH, Kim Y, Choi JW, Kim YS. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis. Eur J Endocrinol 2013;168:343-349.
[CROSSREF] [PUBMED]
30. Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 2013;98:474-482.
[CROSSREF] [PUBMED]
31. Caturegli P, De Remigis A, Chuang K, Dembele M, Iwama A, Iwama S. Hashimoto's thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records. Thyroid 2013;23:142-150.
[CROSSREF] [PUBMED] [PMC]
32. Fiore E, Latrofa F, Vitti P. Iodine, thyroid autoimmunity and cancer. Eur Thyroid J 2015;4:26-35.
[CROSSREF] [PUBMED] [PMC]
33. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011;364:1920-1931.
[CROSSREF] [PUBMED]
34. Watt T, Cramon P, Bjorner JB, Bonnema SJ, Feldt-Rasmussen U, Gluud C, et al. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials 2013;14:119
[CROSSREF] [PUBMED] [PMC]
35. Winther KH, Watt T, Bjorner JB, Cramon P, Feldt-Rasmussen U, Gluud C, et al. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials 2014;15:115
[CROSSREF] [PUBMED] [PMC] [PDF]
36. Gershengorn MC, Neumann S. Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab 2012;97:4287-4292.
[CROSSREF] [PUBMED] [PMC] [PDF]
37. Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab 2013;98:2153-2159.
[CROSSREF] [PUBMED] [PMC] [PDF]
38. Watanabe T, Maruyama M, Ito T, Fujinaga Y, Ozaki Y, Maruyama M, et al. Clinical features of a new disease concept, IgG4-related thyroiditis. Scand J Rheumatol 2013;42:325-330.
[CROSSREF] [PUBMED]
39. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004;292:2591-2599.
[CROSSREF] [PUBMED]
40. Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Greenwood R, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 2014;174:32-39.
[CROSSREF] [PUBMED]
41. Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J 2013;2:215-228.
[CROSSREF] [PUBMED] [PMC]